Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week Double-blind, Randomized, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of SAR425899 for the Treatment of Non-alcoholic Steatohepatitis (NASH)

Trial Profile

A 52-week Double-blind, Randomized, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of SAR425899 for the Treatment of Non-alcoholic Steatohepatitis (NASH)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs SAR 425899 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms Restore
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Oct 2018 Planned End Date changed from 26 May 2021 to 25 Aug 2021.
    • 01 Oct 2018 Planned primary completion date changed from 26 May 2021 to 25 Aug 2021.
    • 01 Oct 2018 Planned initiation date changed from 21 Feb 2019 to 23 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top